Autopsy report · NCT04372641
Testing the Safety of CB-5339 in Patients With Cancer
Cause of deathFunding or business
“Other - Clinical development of the agent has been discontinued”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 1
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- Aggressive Non-Hodgkin Lymphoma; Indolent Non-Hodgkin Lymphoma; Locally Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm
- Interventions
- p97 Inhibitor CB-5339 Tosylate
- Participants
- 0
- Sites
- 2
- Countries
- United States
Trials that died the same way
- RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)
“The sponsor's clinical program for the agent used in this study was discontinued.” - Molar Sodium Lactate Filling in Severe Meningeal Hemorrhage
“The treatments are no longer available.” - An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.
“Trial has been cancelled due to availability of new therapeutic options for patient population” - Giant Cell Arteritis and Anakinra Trial
“experimental treatment no longer available” - Utilization of MAsS in Patients Undergoing LT for HCC
“Discontinued by Amra Medical due to funding.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.